Cargando…

Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses

OBJECTIVE: Exposure‐response (E‐R) models were developed to provide a description of the time‐course of treatment effect for monthly and quarterly dosing regimens of fremanezumab. BACKGROUND: Fremanezumab is a monoclonal antibody for preventive treatment of episodic migraine (EM) and chronic migrain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiedler‐Kelly, Jill, Passarell, Julie, Ludwig, Elizabeth, Levi, Micha, Cohen‐Barak, Orit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496732/ https://www.ncbi.nlm.nih.gov/pubmed/32445498 http://dx.doi.org/10.1111/head.13845

Ejemplares similares

No “Wearing‐Off Effect” Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long‐Term Study
por: Blumenfeld, Andrew M., et al.
Publicado: (2020)

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
por: Fiedler‐Kelly, Jill B., et al.
Publicado: (2019)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
por: Lipton, Richard B., et al.
Publicado: (2021)

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY(®)) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study
por: Jones, Aksana, et al.
Publicado: (2021)

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
por: Suzuki, Shiho, et al.
Publicado: (2023)

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials
por: Schim, Jack D., et al.
Publicado: (2022)

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks
por: Tepper, Stewart J., et al.
Publicado: (2020)

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
por: Dodick, David W., et al.
Publicado: (2020)

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials
por: Ailani, Jessica, et al.
Publicado: (2022)

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
por: Fofi, Luisa, et al.
Publicado: (2022)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics
por: Carr, Chelsea N., et al.
Publicado: (2016)

Using Photovoice to explore patients' experiences with mental health medication: A pilot study
por: Werremeyer, Amy B., et al.
Publicado: (2016)

Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review
por: Carr, Chelsea N., et al.
Publicado: (2016)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Patient preference for early onset of efficacy of preventive migraine treatments
por: Ailani, Jessica, et al.
Publicado: (2022)

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies
por: Ashina, Messoud, et al.
Publicado: (2019)

Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult‐to‐Treat Migraine Headaches
por: Tepper, Stewart J., et al.
Publicado: (2019)

Intravenous administration of mesenchymal stromal cells leads to a dose-dependent coagulopathy and is unable to attenuate acute traumatic coagulopathy in rats
por: Wu, Xiaowu, et al.
Publicado: (2022)

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial
por: Croop, Robert, et al.
Publicado: (2022)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
por: Sakai, Fumihiko, et al.
Publicado: (2021)

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
por: Broessner, Gregor, et al.
Publicado: (2020)

A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy
por: Kinoshita, Shigeru, et al.
Publicado: (2021)

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
por: Ashina, Messoud, et al.
Publicado: (2022)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
por: Takeshima, Takao, et al.
Publicado: (2021)

Long‐Term Efficacy of a Double‐Blind, Placebo‐Controlled, Randomized Study for Repetitive Sphenopalatine Blockade With Bupivacaine vs Saline With the Tx360(®) Device for Treatment of Chronic Migraine
por: Cady, Roger K., et al.
Publicado: (2015)

Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine‐Associated Nausea and Prior Triptan Use on Efficacy
por: Lipton, Richard B., et al.
Publicado: (2017)

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies
por: Smitherman, Todd A., et al.
Publicado: (2020)

Evaluation of provider response to positive depression screenings and physician attitudes on integrating psychiatric pharmacist services in primary care settings
por: Denson, Brittany H., et al.
Publicado: (2018)

STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®)) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients
por: Smith, Timothy R., et al.
Publicado: (2021)

Characterization of Familial and Sporadic Migraine
por: Ravn, Julie, et al.
Publicado: (2019)

Aortic balloon occlusion in distal zone 3 reduces blood loss from obstetric hemorrhage in placenta accreta spectrum
por: Kluck, Sarah L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p7fgj1klm6mgdrjft25hni6frf